China's leading donkey-hide gelatin (Ejiao) maker, selling a traditional tonic product prized for blood and health benefits.
China's leading donkey-hide gelatin (Ejiao) maker, selling a traditional tonic product prized for blood and health benefits.
Sells a premium tonic bought partly as a gift, so brand heritage and the distribution channel matter more than manufacturing. The raw material, donkey hide, is scarce, so its supply and cost are a central lever.
In one line: A single-category Chinese heritage tonic brand.
Moat: narrow (brand, scale). Dominant heritage brand in Ejiao with control over scarce donkey-hide raw material supply.
Headquarters: Liaocheng, Shandong, China · Founded: 1952 · Employees: 4,345
Size Dong-E-E-Jiao (000423.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $4.99B, the 465th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥52.64 on 18 Nov 2026.
Performance Over six months the shares gained 0.7%, against -0.2% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 8.1% over the last twelve months (peer median +10.1%); the operating margin is 29.4% (peer median 15.3%).
Valuation It trades at 17.8× forward earnings against a peer median of 20.6× (8th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 51.5 points above its cost of capital (5.4% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.87B | CN¥6.64B | CN¥6.11B | CN¥4.67B | CN¥4.00B |
| Revenue growth | — | +9% | +31% | +17% | — |
| Gross profit | CN¥5.15B | CN¥4.76B | CN¥4.14B | CN¥3.17B | CN¥2.61B |
| EBITDA | n/a | CN¥2.10B | CN¥1.79B | CN¥1.40B | CN¥1.04B |
| Net income | CN¥1.79B | CN¥1.74B | CN¥1.56B | CN¥1.15B | CN¥780M |
| Free cash flow | CN¥1.15B | CN¥2.30B | CN¥2.85B | CN¥1.95B | CN¥2.18B |
| Capital expenditure | CN¥320M | CN¥82.7M | CN¥97.4M | CN¥54.5M | CN¥45.6M |
| Total debt | CN¥168M | CN¥94.0M | CN¥38.3M | CN¥47.8M | CN¥62.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dong-E-E-Jiao 000423.SZ | $4.99B | +1% | +8% | 29% | 17.8× | -3.7% |
| Jiuzhitang 000989.SZ | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000423.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.2% | -0.5% | 5th highest of 21 |
| 6-month return | +0.7% | -0.2% | 10th highest of 21 |
| Distance from 52-week high | -9.8% | -22.6% | 6th highest of 21 |
| Revenue growth (TTM) | +8.1% | +10.1% | 10th lowest of 20 |
| Operating margin | 29.4% | 15.3% | 3rd highest of 20 |
| Forward P/E | 17.8× | 20.6× | 8th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -3.7% | 0.4% | 6th least demanding of 19 |
| Growth delivered (Del g) | +14.5% | +6.1% | 3rd highest of 19 |
| Hurdle (Req g minus delivered) | -18.3 pp | -3.0 pp | 3rd least demanding of 19 |
| ROIC minus cost of capital | +51.5 pp | +2.6 pp | highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dong-E-E-Jiao 000423.SZ | China | $4.99B | +1% | +8% | 29% | 17.8× | -3.7% | +14.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% | -2.2% |
| Abivax ABVX.PA | France | $7.36B | -30% | n/a | n/a | n/a | n/a | n/a |
| Bausch Health Companies BHC.TO | Canada | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% | +5.9% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.00B | +11% | -14% | 9% | 91.7× | 33.8% | +5.9% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $2.97B | -7% | -4% | -13% | n/a | 5.0% | +1.0% |
| Lupin LUPIN.NS | India | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% | +13.0% |
| By-health 300146.SZ | China | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% | +0.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% | +5.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |
| Aurobindo Pharma AUROPHARMA.NS | India | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% | +6.3% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| Zhejiang NHU 002001.SZ | China | $11.8B | -22% | +11% | 33% | 9.7× | -8.3% | +16.7% |
| Cipla CIPLA.NS | India | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% | +8.1% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |